The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-277

I like your thoughts. To me it’s about timing and structure of any capital raise. Logically it would be after topline results and ODD decision as they would know the playing field for costs. Also SP peak to minimise dilution and sand bag raise price.

Timing is tight if planning on partnering as the red tape would delay commencement. It would good to secure funding post ODD and partner with cash in the bank so no low balling offer if Pharma see PAA in desperate need of cash.

Interested to see how it all plays out. SPP and oppies seems to be the current market trend. Need cash straight away is the issue.